Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
NCT ID: NCT06526858
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
15 participants
INTERVENTIONAL
2024-11-21
2029-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension
NCT06216808
Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension
NCT07108829
Renal Denervation for Uncontrolled Hypertension
NCT02016573
Renal Denervation in Hypertension
NCT01570777
Rapid Renal Sympathetic Denervation for Resistant Hypertension
NCT01520506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\<Background and Hypothesis\> The HyperQureTM RDN System is developed to overcome the limitations of intravascular RDN using catheters; 1)incomplete renal denervation, 2) risk of endothelial damage due to heat transfer from inside blood vessels by intravascular access, and 3) access limitations due to vascular anatomy and vessel size.
The HyperQureTM RDN System is accessed through the vascular adventitia where renal sympathetic nerves are mainly distributed by retroperitoneal laparoscopic(extravascular) approach . Since the energy is transmitted from outside of vessel by wrapping the blood vessel 360 degrees and the instrument is applicable to small vessels including branch and/or accessory vessels, it is expected that it will be possible to achieve more complete renal denervation, reduce the risk of endothelial damage, and resolve structural access limitations.
\<Study plan\> Fifteen eligible adult men and women with resistant hypertension will be enrolled and will have Extravascular(laparoscopic) RDN under general anesthesia and will have 36month follow up with various BP evaluations(24hABP, Office BP and Home BP) and CTA/DUS imaging scan evaluations
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Extravsacular(Laparoscopic) Renal Denervation
Intervention:
Device: HyperQureTM Renal Denervation (RDN) System:
* HyperQureTM RDN Generator
* HyperQureTM RDN Laparoscopic Instrument
HyperQureTM Renal Denervation (RDN) System:
The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.
The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HyperQureTM Renal Denervation (RDN) System:
The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.
The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Aged ≥22 and ≤80 years old at time of enrollment (consent).
2. Diagnosed with resistant hypertension.
3. Office BP ≥140/90 mmHg at Screening Visit 1, and on at least 3 antihypertensive medications of different classes including a diuretic for at least 4 weeks prior to consent.
4. Daytime ABP ≥135/85 mmHg after a four (4)-week run-in period at Screening Visit 2.
5. Agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study.
Exclusion Criteria
1. Has coverage diameter of renal artery less than 2 mm or greater than 11 mm.
2. Has one or more of the following conditions:
1. Unstable angina with stent implantation (percutaneous coronary intervention) within 3 months of enrolment.
2. Myocardial infarction within 3 months of enrollment.
3. Acute heart failure (New York Heart Association (NYHA) III-IV) within 3 months of enrollment
4. Cerebrovascular accident or transient ischemic attack within 3 months of enrollment.
5. Atrial fibrillation patients undergoing treatment and not in sinus rhythm. Notes: Patients who have received medical treatment, catheter or surgical treatment for atrial fibrillation and are in sinus rhythm are not excluded
3. Has one or more of the following confirmed anatomical findings in the kidney or renal artery that are not suitable for renal denervation (assessed by the renal CT angiography of Screening 2)
1. A single functioning kidney.
2. An atheroma, aneurysm or renal artery stent within 5 mm of the renal denervation site.
3. Presence of stenosis of 30% or more on all of the blood vessels available for renal denervation therapy.
4. When it is deemed impossible to perform denervation on both renal arteries according to the discretion of the investigator.
4. Has one or more of the following medical history or a history of surgery/procedure that is not suitable for renal denervation therapy
1. Renal denervation therapy.
2. Polycystic kidney disease (PKD).
3. Atrophic kidney.
4. Kidney transplant.
5. Dialysis due to end-stage renal disease.
6. Any surgery performed on both kidneys. (except endoscopy type of surgery, i.e. endoscopic kidney stone removal)
7. FMD (Fibromuscular dysplasia)
5. Has comorbidities or surgical/procedural history that are not suitable for retroperitoneal approach
1. Surgical history through retroperitoneal approach.
2. Fibrosis in the retroperitoneal region.
3. Inflammation in the retroperitoneal region.
4. Severe obesity (body mass index (BMI) \> 40 kg/m2)
5. Risk of increased intracranial pressure
6. Has a history of any intervention for underlying renal artery pathology including stenting or balloon angioplasty.
7. Individual has an eGFR of \<45 mL/min/1.73m2, using the 4 variable Modification of Diet in Renal Disease (MDRD) calculation (in mL/min) per 1.73 m2 = 175 x Serum Cr-1.154 x age-0.203 x 1.212 (if patient is black) x 0.742 (if female).
8. Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma Hb1Ac ≥ 9.0%).
9. Has had a reduction of SBP of ≥20 mm Hg or DBP of ≥10 mm Hg within 3 minutes of standing coupled with symptoms during the screening process (at Screening Visit 2).
10. Requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea (e.g., CPAP, BiPAP).
11. Has documented primary pulmonary hypertension.
12. Has an untreated secondary cause of hypertension (either known or suspected) or is taking drugs that increase sympathetic tone and could contribute to hypertension.
13. Has a scheduled or planned surgery that, in the opinion of the Investigator, may affect study endpoints.
14. Works night shifts.
15. Has severe cardiac valve stenosis for which, in the opinion of the Investigator, a significant reduction of blood pressure is contraindicated.
16. Is pregnant, nursing or planning to become pregnant during the course of the study follow-up (Note: Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (hCG) pregnancy test prior to angiography).
17. Has a known unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable, in the opinion of the Investigator, to comply with study follow-up requirements.
18. Has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
19. Patients who are at high risk if taken off their anticoagulant and antiplatelet agents for a few days.
20. Allergy, intolerance or contraindications to contrast medium.
21. Prescribed any standard antihypertensive cardiovascular medication for other chronic conditions (e.g. ischemic heart disease) for less than 90 days before Screening visit 1 and whose discontinuation might pose serious risk to health.
22. Has frequent intermittent or chronic pain that results in the treatment with non-steroidal anti-inflammatory drugs (NSAIDs) for two (2) or more days per week over the month prior to Screening Visit 2.
23. Concurrent enrollment in any other investigational drug or device study(Participation in non-interventional Registries is acceptable).
22 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DeepQure Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Irvine
Orange, California, United States
Stanford Health Care
Stanford, California, United States
University of Florida College of Medicine
Gainesville, Florida, United States
Henry Forth Health
Detroit, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HQ-HTN-G01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.